Fate Therapeutics Inc
FATE1.070USD
-0.030-2.73%
Fechamento 08/01, 16:00（ET）Cotações atrasadas em 15 min
122.63MValor de mercado
PerdaP/L TTM
Mais detalhes de Fate Therapeutics Inc Empresa
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Informações da empresa
Código da empresaFATE
Nome da EmpresaFate Therapeutics Inc
Data de listagemOct 01, 2013
Fundado em2007
CEODr. Bahram Valamehr, Ph.D.
Número de funcionários181
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 01
Endereço12278 Scripps Summit Drive
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92131
Telefone18588751803
Sitehttps://fatetherapeutics.com/
Código da empresaFATE
Data de listagemOct 01, 2013
Fundado em2007
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 22 de mai
Atualizado em: qui, 22 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Redmile Group, LLC
11.24%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
7.65%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
58.00%
Investidores
Investidores
Proporção
Redmile Group, LLC
11.24%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
7.65%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
58.00%
Tipos de investidores
Investidores
Proporção
Investment Advisor
33.06%
Investment Advisor/Hedge Fund
28.53%
Hedge Fund
19.14%
Research Firm
6.44%
Venture Capital
3.35%
Individual Investor
1.74%
Private Equity
1.47%
Bank and Trust
0.36%
Pension Fund
0.15%
Other
5.76%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
417
108.07M
94.28%
-29.73M
2025Q1
445
110.00M
95.96%
-29.05M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Redmile Group, LLC
12.87M
11.23%
--
--
Mar 31, 2025
ARK Investment Management LLC
10.31M
9%
+10.31M
--
Mar 31, 2025
The Vanguard Group, Inc.
10.31M
8.99%
-22.58K
-0.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
7.32%
-99.57K
-1.17%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
7.79M
6.8%
+7.79M
--
Mar 31, 2025
Citadel Advisors LLC
4.29M
3.74%
-93.10K
-2.12%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
3.26M
2.84%
--
--
Mar 31, 2025
JP Morgan Asset Management
2.76M
2.41%
+1.63M
+144.44%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.59M
2.26%
-306.82K
-10.59%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.66%
WisdomTree BioRevolution Fund
0.65%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.66%
WisdomTree BioRevolution Fund
Proporção0.65%
Invesco Nasdaq Biotechnology ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.01%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
Schwab U.S. Broad Market ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
iShares Genomics Immunology and Healthcare ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
